APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neuroblastoma Treatment

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Neuroblastoma Treatment Market Analysis and Forecast 2026-2032

19 December 2025197 pages

Choose your research edition.

Industry ResearchNeuroblastoma Treatment Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Neuroblastoma Treatment Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Neuroblastoma Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neuroblastoma Treatment Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Neuroblastoma Treatment Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Neuroblastoma Treatment market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Neuroblastoma Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Neuroblastoma Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Neuroblastoma Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Neuroblastoma Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Neuroblastoma Treatment include Adaptimmune, CureSearch, Juno Therapeutics, Kite Pharma, NANT, Seattle Children’s, Texas Children’s, Fosun Pharmaceutical and Jiangsu Hengrui Medicine Co.,Ltd., etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Neuroblastoma Treatment, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Neuroblastoma Treatment, also provides the revenue of main regions and countries. Of the upcoming market potential for Neuroblastoma Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Neuroblastoma Treatment revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Neuroblastoma Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Neuroblastoma Treatment revenue, projected growth trends, production technology, application and end-user industry.

Neuroblastoma Treatment Segment by Company

Adaptimmune

CureSearch

Juno Therapeutics

Kite Pharma

NANT

Seattle Children’s

Texas Children’s

Fosun Pharmaceutical

Jiangsu Hengrui Medicine Co.,Ltd.

Novartis

Sino Biopharmaceutical

Neuroblastoma Treatment Segment by Type

Vaccine Therapy

Oncolytic Virus Therapy

Chimeric Antigen Receptor T-Cell Immunotherapy

Combination Chemotherapy

Monoclonal Antibody Therapy

Neuroblastoma Treatment Segment by Application

Hospitals

Clinics

Others

Neuroblastoma Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuroblastoma Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neuroblastoma Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuroblastoma Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Neuroblastoma Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Neuroblastoma Treatment company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neuroblastoma Treatment revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Neuroblastoma Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Vaccine Therapy Major Player Table 3. Oncolytic Virus Therapy Major Player Table 4. Chimeric Antigen Receptor T-Cell Immunotherapy Major Player Table 5. Combination Chemotherapy Major Player Table 6. Monoclonal Antibody Therapy Major Player Table 7. Global Neuroblastoma Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Hospitals Major Player Table 9. Clinics Major Player Table 10. Others Major Player Table 11. Neuroblastoma Treatment Industry Trends Table 12. Neuroblastoma Treatment Industry Drivers Table 13. Neuroblastoma Treatment Industry Opportunities and Challenges Table 14. Neuroblastoma Treatment Industry Restraints Table 15. Global Neuroblastoma Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Neuroblastoma Treatment Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Neuroblastoma Treatment Market Share by Region (2021-2026) Table 18. Global Neuroblastoma Treatment Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Neuroblastoma Treatment Market Share by Region (2027-2032) Table 20. Global Neuroblastoma Treatment Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Neuroblastoma Treatment Revenue Market Share by Players (2021-2026) Table 22. Global Neuroblastoma Treatment Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Neuroblastoma Treatment Key Players Headquarters & Area Served Table 24. Global Neuroblastoma Treatment Players, Product Type & Application Table 25. Global Neuroblastoma Treatment Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Neuroblastoma Treatment by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Neuroblastoma Treatment Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Neuroblastoma Treatment Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Neuroblastoma Treatment Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Neuroblastoma Treatment Revenue Market Share by Type (2021-2026) Table 32. Global Neuroblastoma Treatment Revenue Market Share by Type (2027-2032) Table 33. Global Neuroblastoma Treatment Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Neuroblastoma Treatment Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Neuroblastoma Treatment Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Neuroblastoma Treatment Revenue Market Share by Application (2021-2026) Table 37. Global Neuroblastoma Treatment Revenue Market Share by Application (2027-2032) Table 38. Adaptimmune Company Information Table 39. Adaptimmune Business Overview Table 40. Adaptimmune Neuroblastoma Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Adaptimmune Neuroblastoma Treatment Product Portfolio Table 42. Adaptimmune Recent Development Table 43. CureSearch Company Information Table 44. CureSearch Business Overview Table 45. CureSearch Neuroblastoma Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. CureSearch Neuroblastoma Treatment Product Portfolio Table 47. CureSearch Recent Development Table 48. Juno Therapeutics Company Information Table 49. Juno Therapeutics Business Overview Table 50. Juno Therapeutics Neuroblastoma Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Juno Therapeutics Neuroblastoma Treatment Product Portfolio Table 52. Juno Therapeutics Recent Development Table 53. Kite Pharma Company Information Table 54. Kite Pharma Business Overview Table 55. Kite Pharma Neuroblastoma Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Kite Pharma Neuroblastoma Treatment Product Portfolio Table 57. Kite Pharma Recent Development Table 58. NANT Company Information Table 59. NANT Business Overview Table 60. NANT Neuroblastoma Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. NANT Neuroblastoma Treatment Product Portfolio Table 62. NANT Recent Development Table 63. Seattle Children’s Company Information Table 64. Seattle Children’s Business Overview Table 65. Seattle Children’s Neuroblastoma Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Seattle Children’s Neuroblastoma Treatment Product Portfolio Table 67. Seattle Children’s Recent Development Table 68. Texas Children’s Company Information Table 69. Texas Children’s Business Overview Table 70. Texas Children’s Neuroblastoma Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Texas Children’s Neuroblastoma Treatment Product Portfolio Table 72. Texas Children’s Recent Development Table 73. Fosun Pharmaceutical Company Information Table 74. Fosun Pharmaceutical Business Overview Table 75. Fosun Pharmaceutical Neuroblastoma Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Fosun Pharmaceutical Neuroblastoma Treatment Product Portfolio Table 77. Fosun Pharmaceutical Recent Development Table 78. Jiangsu Hengrui Medicine Co.,Ltd. Company Information Table 79. Jiangsu Hengrui Medicine Co.,Ltd. Business Overview Table 80. Jiangsu Hengrui Medicine Co.,Ltd. Neuroblastoma Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. Jiangsu Hengrui Medicine Co.,Ltd. Neuroblastoma Treatment Product Portfolio Table 82. Jiangsu Hengrui Medicine Co.,Ltd. Recent Development Table 83. Novartis Company Information Table 84. Novartis Business Overview Table 85. Novartis Neuroblastoma Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. Novartis Neuroblastoma Treatment Product Portfolio Table 87. Novartis Recent Development Table 88. Sino Biopharmaceutical Company Information Table 89. Sino Biopharmaceutical Business Overview Table 90. Sino Biopharmaceutical Neuroblastoma Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Sino Biopharmaceutical Neuroblastoma Treatment Product Portfolio Table 92. Sino Biopharmaceutical Recent Development Table 93. North America Neuroblastoma Treatment Revenue by Type (2021-2026) & (US$ Million) Table 94. North America Neuroblastoma Treatment Revenue by Type (2027-2032) & (US$ Million) Table 95. North America Neuroblastoma Treatment Revenue by Application (2021-2026) & (US$ Million) Table 96. North America Neuroblastoma Treatment Revenue by Application (2027-2032) & (US$ Million) Table 97. North America Neuroblastoma Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 98. North America Neuroblastoma Treatment Revenue by Country (2021-2026) & (US$ Million) Table 99. North America Neuroblastoma Treatment Revenue by Country (US$ Million) & (2027-2032) Table 100. Europe Neuroblastoma Treatment Revenue by Type (2021-2026) & (US$ Million) Table 101. Europe Neuroblastoma Treatment Revenue by Type (2027-2032) & (US$ Million) Table 102. Europe Neuroblastoma Treatment Revenue by Application (2021-2026) & (US$ Million) Table 103. Europe Neuroblastoma Treatment Revenue by Application (2027-2032) & (US$ Million) Table 104. Europe Neuroblastoma Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 105. Europe Neuroblastoma Treatment Revenue by Country (2021-2026) & (US$ Million) Table 106. Europe Neuroblastoma Treatment Revenue by Country (US$ Million) & (2027-2032) Table 107. China Neuroblastoma Treatment Revenue by Type (2021-2026) & (US$ Million) Table 108. China Neuroblastoma Treatment Revenue by Type (2027-2032) & (US$ Million) Table 109. China Neuroblastoma Treatment Revenue by Application (2021-2026) & (US$ Million) Table 110. China Neuroblastoma Treatment Revenue by Application (2027-2032) & (US$ Million) Table 111. Asia Neuroblastoma Treatment Revenue by Type (2021-2026) & (US$ Million) Table 112. Asia Neuroblastoma Treatment Revenue by Type (2027-2032) & (US$ Million) Table 113. Asia Neuroblastoma Treatment Revenue by Application (2021-2026) & (US$ Million) Table 114. Asia Neuroblastoma Treatment Revenue by Application (2027-2032) & (US$ Million) Table 115. Asia Neuroblastoma Treatment Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 116. Asia Neuroblastoma Treatment Revenue by Region (US$ Million) & (2021-2026) Table 117. Asia Neuroblastoma Treatment Revenue by Region (US$ Million) & (2027-2032) Table 118. SAMEA Neuroblastoma Treatment Revenue by Type (2021-2026) & (US$ Million) Table 119. SAMEA Neuroblastoma Treatment Revenue by Type (2027-2032) & (US$ Million) Table 120. SAMEA Neuroblastoma Treatment Revenue by Application (2021-2026) & (US$ Million) Table 121. SAMEA Neuroblastoma Treatment Revenue by Application (2027-2032) & (US$ Million) Table 122. SAMEA Neuroblastoma Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 123. SAMEA Neuroblastoma Treatment Revenue by Country (2021-2026) & (US$ Million) Table 124. SAMEA Neuroblastoma Treatment Revenue by Country (US$ Million) & (2027-2032) Table 125. Research Programs/Design for This Report Table 126. Authors List of This Report Table 127. Secondary Sources Table 128. Primary Sources List of Figures Figure 1. Neuroblastoma Treatment Image Figure 2. Global Neuroblastoma Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neuroblastoma Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 4. Vaccine Therapy Image Figure 5. Oncolytic Virus Therapy Image Figure 6. Chimeric Antigen Receptor T-Cell Immunotherapy Image Figure 7. Combination Chemotherapy Image Figure 8. Monoclonal Antibody Therapy Image Figure 9. Global Neuroblastoma Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Neuroblastoma Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 11. Hospitals Image Figure 12. Clinics Image Figure 13. Others Image Figure 14. Global Neuroblastoma Treatment Market Size (US$ Million) & (2021-2032) Figure 15. Global Neuroblastoma Treatment Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Neuroblastoma Treatment Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Neuroblastoma Treatment Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Neuroblastoma Treatment Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Neuroblastoma Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Neuroblastoma Treatment Revenue Market Share by Type (2021-2032) Figure 22. Global Neuroblastoma Treatment Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Neuroblastoma Treatment Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Neuroblastoma Treatment Revenue Market Share by Application (2021-2032) Figure 25. North America Neuroblastoma Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Neuroblastoma Treatment Revenue Share by Type (2021-2032) Figure 27. North America Neuroblastoma Treatment Revenue Share by Application (2021-2032) Figure 28. North America Neuroblastoma Treatment Revenue Share by Country (2021-2032) Figure 29. United States Neuroblastoma Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Neuroblastoma Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Neuroblastoma Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Neuroblastoma Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Neuroblastoma Treatment Revenue Share by Type (2021-2032) Figure 34. Europe Neuroblastoma Treatment Revenue Share by Application (2021-2032) Figure 35. Europe Neuroblastoma Treatment Revenue Share by Country (2021-2032) Figure 36. Germany Neuroblastoma Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Neuroblastoma Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Neuroblastoma Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Neuroblastoma Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Neuroblastoma Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Neuroblastoma Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Neuroblastoma Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Neuroblastoma Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Neuroblastoma Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Neuroblastoma Treatment Revenue Share by Type (2021-2032) Figure 46. China Neuroblastoma Treatment Revenue Share by Application (2021-2032) Figure 47. Asia Neuroblastoma Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Neuroblastoma Treatment Revenue Share by Type (2021-2032) Figure 49. Asia Neuroblastoma Treatment Revenue Share by Application (2021-2032) Figure 50. Asia Neuroblastoma Treatment Revenue Share by Region (2021-2032) Figure 51. Japan Neuroblastoma Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Neuroblastoma Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Neuroblastoma Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Neuroblastoma Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Neuroblastoma Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Neuroblastoma Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Neuroblastoma Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Neuroblastoma Treatment Revenue Share by Type (2021-2032) Figure 59. SAMEA Neuroblastoma Treatment Revenue Share by Application (2021-2032) Figure 60. SAMEA Neuroblastoma Treatment Revenue Share by Country (2021-2032) Figure 61. Brazil Neuroblastoma Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Neuroblastoma Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Neuroblastoma Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Neuroblastoma Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Neuroblastoma Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Neuroblastoma Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Neuroblastoma Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Neuroblastoma Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Neuroblastoma Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Neuroblastoma Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Neuroblastoma Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Vaccine Therapy
  • Oncolytic Virus Therapy
  • Chimeric Antigen Receptor T-Cell Immunotherapy
  • Combination Chemotherapy
  • Monoclonal Antibody Therapy
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Adaptimmune
  • CureSearch
  • Juno Therapeutics
  • Kite Pharma
  • NANT
  • Seattle Children’s
  • Texas Children’s
  • Fosun Pharmaceutical
  • Jiangsu Hengrui Medicine Co.,Ltd.
  • Novartis
  • Sino Biopharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Neuroblastoma Treatment Market by Type
  3. 1.2.1 Global Neuroblastoma Treatment Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Vaccine Therapy
  5. 1.2.3 Oncolytic Virus Therapy
  6. 1.2.4 Chimeric Antigen Receptor T-Cell Immunotherapy
  7. 1.2.5 Combination Chemotherapy
  8. 1.2.6 Monoclonal Antibody Therapy
  9. 1.3 Neuroblastoma Treatment Market by Application
  10. 1.3.1 Global Neuroblastoma Treatment Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Hospitals
  12. 1.3.3 Clinics
  13. 1.3.4 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Neuroblastoma Treatment Market Dynamics
  1. 2.1 Neuroblastoma Treatment Industry Trends
  2. 2.2 Neuroblastoma Treatment Industry Drivers
  3. 2.3 Neuroblastoma Treatment Industry Opportunities and Challenges
  4. 2.4 Neuroblastoma Treatment Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Neuroblastoma Treatment Market Perspective (2021-2032)
  2. 3.2 Global Neuroblastoma Treatment Growth Trends by Region
  3. 3.2.1 Global Neuroblastoma Treatment Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Neuroblastoma Treatment Market Size by Region (2021-2026)
  5. 3.2.3 Global Neuroblastoma Treatment Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Neuroblastoma Treatment Revenue by Players
  2. 4.1.1 Global Neuroblastoma Treatment Revenue by Players (2021-2026)
  3. 4.1.2 Global Neuroblastoma Treatment Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Neuroblastoma Treatment Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Neuroblastoma Treatment Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Neuroblastoma Treatment Key Players Headquarters & Area Served
  7. 4.4 Global Neuroblastoma Treatment Players, Product Type & Application
  8. 4.5 Global Neuroblastoma Treatment Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Neuroblastoma Treatment Market CR5 and HHI
  11. 4.6.3 2025 Neuroblastoma Treatment Tier 1, Tier 2, and Tier 3
5 Neuroblastoma Treatment Market Size by Type
  1. 5.1 Global Neuroblastoma Treatment Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Neuroblastoma Treatment Revenue by Type (2021-2032)
  3. 5.3 Global Neuroblastoma Treatment Revenue Market Share by Type (2021-2032)
6 Neuroblastoma Treatment Market Size by Application
  1. 6.1 Global Neuroblastoma Treatment Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Neuroblastoma Treatment Revenue by Application (2021-2032)
  3. 6.3 Global Neuroblastoma Treatment Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Adaptimmune
  2. 7.1.1 Adaptimmune Company Information
  3. 7.1.2 Adaptimmune Business Overview
  4. 7.1.3 Adaptimmune Neuroblastoma Treatment Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Adaptimmune Neuroblastoma Treatment Product Portfolio
  6. 7.1.5 Adaptimmune Recent Developments
  7. 7.2 CureSearch
  8. 7.2.1 CureSearch Company Information
  9. 7.2.2 CureSearch Business Overview
  10. 7.2.3 CureSearch Neuroblastoma Treatment Revenue and Gross Margin (2021-2026)
  11. 7.2.4 CureSearch Neuroblastoma Treatment Product Portfolio
  12. 7.2.5 CureSearch Recent Developments
  13. 7.3 Juno Therapeutics
  14. 7.3.1 Juno Therapeutics Company Information
  15. 7.3.2 Juno Therapeutics Business Overview
  16. 7.3.3 Juno Therapeutics Neuroblastoma Treatment Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Juno Therapeutics Neuroblastoma Treatment Product Portfolio
  18. 7.3.5 Juno Therapeutics Recent Developments
  19. 7.4 Kite Pharma
  20. 7.4.1 Kite Pharma Company Information
  21. 7.4.2 Kite Pharma Business Overview
  22. 7.4.3 Kite Pharma Neuroblastoma Treatment Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Kite Pharma Neuroblastoma Treatment Product Portfolio
  24. 7.4.5 Kite Pharma Recent Developments
  25. 7.5 NANT
  26. 7.5.1 NANT Company Information
  27. 7.5.2 NANT Business Overview
  28. 7.5.3 NANT Neuroblastoma Treatment Revenue and Gross Margin (2021-2026)
  29. 7.5.4 NANT Neuroblastoma Treatment Product Portfolio
  30. 7.5.5 NANT Recent Developments
  31. 7.6 Seattle Children’s
  32. 7.6.1 Seattle Children’s Company Information
  33. 7.6.2 Seattle Children’s Business Overview
  34. 7.6.3 Seattle Children’s Neuroblastoma Treatment Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Seattle Children’s Neuroblastoma Treatment Product Portfolio
  36. 7.6.5 Seattle Children’s Recent Developments
  37. 7.7 Texas Children’s
  38. 7.7.1 Texas Children’s Company Information
  39. 7.7.2 Texas Children’s Business Overview
  40. 7.7.3 Texas Children’s Neuroblastoma Treatment Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Texas Children’s Neuroblastoma Treatment Product Portfolio
  42. 7.7.5 Texas Children’s Recent Developments
  43. 7.8 Fosun Pharmaceutical
  44. 7.8.1 Fosun Pharmaceutical Company Information
  45. 7.8.2 Fosun Pharmaceutical Business Overview
  46. 7.8.3 Fosun Pharmaceutical Neuroblastoma Treatment Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Fosun Pharmaceutical Neuroblastoma Treatment Product Portfolio
  48. 7.8.5 Fosun Pharmaceutical Recent Developments
  49. 7.9 Jiangsu Hengrui Medicine Co.,Ltd.
  50. 7.9.1 Jiangsu Hengrui Medicine Co.,Ltd. Company Information
  51. 7.9.2 Jiangsu Hengrui Medicine Co.,Ltd. Business Overview
  52. 7.9.3 Jiangsu Hengrui Medicine Co.,Ltd. Neuroblastoma Treatment Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Jiangsu Hengrui Medicine Co.,Ltd. Neuroblastoma Treatment Product Portfolio
  54. 7.9.5 Jiangsu Hengrui Medicine Co.,Ltd. Recent Developments
  55. 7.10 Novartis
  56. 7.10.1 Novartis Company Information
  57. 7.10.2 Novartis Business Overview
  58. 7.10.3 Novartis Neuroblastoma Treatment Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Novartis Neuroblastoma Treatment Product Portfolio
  60. 7.10.5 Novartis Recent Developments
  61. 7.11 Sino Biopharmaceutical
  62. 7.11.1 Sino Biopharmaceutical Company Information
  63. 7.11.2 Sino Biopharmaceutical Business Overview
  64. 7.11.3 Sino Biopharmaceutical Neuroblastoma Treatment Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Sino Biopharmaceutical Neuroblastoma Treatment Product Portfolio
  66. 7.11.5 Sino Biopharmaceutical Recent Developments
8 North America
  1. 8.1 North America Neuroblastoma Treatment Revenue (2021-2032)
  2. 8.2 North America Neuroblastoma Treatment Revenue by Type (2021-2032)
  3. 8.2.1 North America Neuroblastoma Treatment Revenue by Type (2021-2026)
  4. 8.2.2 North America Neuroblastoma Treatment Revenue by Type (2027-2032)
  5. 8.3 North America Neuroblastoma Treatment Revenue Share by Type (2021-2032)
  6. 8.4 North America Neuroblastoma Treatment Revenue by Application (2021-2032)
  7. 8.4.1 North America Neuroblastoma Treatment Revenue by Application (2021-2026)
  8. 8.4.2 North America Neuroblastoma Treatment Revenue by Application (2027-2032)
  9. 8.5 North America Neuroblastoma Treatment Revenue Share by Application (2021-2032)
  10. 8.6 North America Neuroblastoma Treatment Revenue by Country
  11. 8.6.1 North America Neuroblastoma Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Neuroblastoma Treatment Revenue by Country (2021-2026)
  13. 8.6.3 North America Neuroblastoma Treatment Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Neuroblastoma Treatment Revenue (2021-2032)
  2. 9.2 Europe Neuroblastoma Treatment Revenue by Type (2021-2032)
  3. 9.2.1 Europe Neuroblastoma Treatment Revenue by Type (2021-2026)
  4. 9.2.2 Europe Neuroblastoma Treatment Revenue by Type (2027-2032)
  5. 9.3 Europe Neuroblastoma Treatment Revenue Share by Type (2021-2032)
  6. 9.4 Europe Neuroblastoma Treatment Revenue by Application (2021-2032)
  7. 9.4.1 Europe Neuroblastoma Treatment Revenue by Application (2021-2026)
  8. 9.4.2 Europe Neuroblastoma Treatment Revenue by Application (2027-2032)
  9. 9.5 Europe Neuroblastoma Treatment Revenue Share by Application (2021-2032)
  10. 9.6 Europe Neuroblastoma Treatment Revenue by Country
  11. 9.6.1 Europe Neuroblastoma Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Neuroblastoma Treatment Revenue by Country (2021-2026)
  13. 9.6.3 Europe Neuroblastoma Treatment Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
  19. 9.6.9 Nordic Countries
10 China
  1. 10.1 China Neuroblastoma Treatment Revenue (2021-2032)
  2. 10.2 China Neuroblastoma Treatment Revenue by Type (2021-2032)
  3. 10.2.1 China Neuroblastoma Treatment Revenue by Type (2021-2026)
  4. 10.2.2 China Neuroblastoma Treatment Revenue by Type (2027-2032)
  5. 10.3 China Neuroblastoma Treatment Revenue Share by Type (2021-2032)
  6. 10.4 China Neuroblastoma Treatment Revenue by Application (2021-2032)
  7. 10.4.1 China Neuroblastoma Treatment Revenue by Application (2021-2026)
  8. 10.4.2 China Neuroblastoma Treatment Revenue by Application (2027-2032)
  9. 10.5 China Neuroblastoma Treatment Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Neuroblastoma Treatment Revenue (2021-2032)
  2. 11.2 Asia Neuroblastoma Treatment Revenue by Type (2021-2032)
  3. 11.2.1 Asia Neuroblastoma Treatment Revenue by Type (2021-2026)
  4. 11.2.2 Asia Neuroblastoma Treatment Revenue by Type (2027-2032)
  5. 11.3 Asia Neuroblastoma Treatment Revenue Share by Type (2021-2032)
  6. 11.4 Asia Neuroblastoma Treatment Revenue by Application (2021-2032)
  7. 11.4.1 Asia Neuroblastoma Treatment Revenue by Application (2021-2026)
  8. 11.4.2 Asia Neuroblastoma Treatment Revenue by Application (2027-2032)
  9. 11.5 Asia Neuroblastoma Treatment Revenue Share by Application (2021-2032)
  10. 11.6 Asia Neuroblastoma Treatment Revenue by Country
  11. 11.6.1 Asia Neuroblastoma Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Neuroblastoma Treatment Revenue by Country (2021-2026)
  13. 11.6.3 Asia Neuroblastoma Treatment Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Neuroblastoma Treatment Revenue (2021-2032)
  2. 12.2 SAMEA Neuroblastoma Treatment Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Neuroblastoma Treatment Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Neuroblastoma Treatment Revenue by Type (2027-2032)
  5. 12.3 SAMEA Neuroblastoma Treatment Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Neuroblastoma Treatment Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Neuroblastoma Treatment Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Neuroblastoma Treatment Revenue by Application (2027-2032)
  9. 12.5 SAMEA Neuroblastoma Treatment Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Neuroblastoma Treatment Revenue by Country
  11. 12.6.1 SAMEA Neuroblastoma Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Neuroblastoma Treatment Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Neuroblastoma Treatment Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst